P. Pazzi et al., SHORT-TERM LOW-DOSE PANTOPRAZOLE-BASED TRIPLE THERAPY FOR CURE OF HELICOBACTER-PYLORI INFECTION IN DUODENAL-ULCER PATIENTS, Alimentary pharmacology & therapeutics, 12(8), 1998, pp. 731-734
Background: The eradication of Helicobacter pylori infection has been
achieved using various therapy regimens, but the efficacy of the proto
n-pump inhibitor pantoprazole as part of these regimens has not yet be
en widely tested. Aim: To evaluate the efficacy and tolerability of a
1-week low-dose pantoprazole-based triple therapy in patients with H.
pylori-positive duodenal ulcer. Methods: In an open single-centre pros
pective study, 71 patients with endoscopically proven active duodenal
ulcer and H, pylori infection received pantoprazole 40 mg o.m. for 4 w
eeks, and during the first week a combination antimicrobial treatment
comprising tinidazole 500 mg b.d. plus clarithomycin 250 mg b.d. H. py
lori eradication was defined as concordant negative histology and rapi
d urease test performed at endoscopy 4-6 weeks after the end of treatm
ent, confirmed 4 weeks later by C-13-urea breath test. Results: Sixty-
six patients (93%) completed the trial and five patients were lost to
follow-up. H, pylori infection was cured in 61 out of the 66 patients
who completed the trial (per-protocol analysis: 92.4%, 95% CI: 83.2-97
.5%; intention-to-treat analysis: 85.9%, 95% CI: 75.7-93.0%), At anal
endoscopy, 65 out of 66 patients had healed ulcer (98.5%). Mild advers
e events occurred in six patients (9.1%). Conclusions: One-week low-do
se pantoprazole-based triple therapy is a simple, effective and well-t
olerated regimen for ulcer healing and H. pylori eradication in patien
ts with duodenal ulcer.